People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Other Technology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vizgen, Inc. | — | Biotechnology | Series D+ | $295.1M | $319.9M | 2021 |
| Arbor Biotechnologies, Inc. | — | Biotechnology | Series D+ | $230.6M | $5.7B | 2021 |
| Nanosys, Inc. | — | Other Technology | Series B | $96.9M | $296.3M | 2010 |
| ADESTO TECHNOLOGIES Corp | — | Other Technology | Series B | $74.4M | $23.9M | 2009 |
| Quanterix Corp | — | Other Technology | Series C | $71.8M | $194.1M | 2013 |
| 908 Devices Inc. | — | Other Technology | Series B | $68.2M | $533.0M | 2013 |
| Ultivue, Inc. | — | Biotechnology | Series B | $55.2M | $23.4M | 2017 |
| Boreal Genomics Inc. | — | Biotechnology | Series B | $24.5M | $714.4M | 2013 |
| Univa Corp | — | Other | Series A | $16.6M | $52.8M | 2009 |
| Crystal IS Inc | — | Other Technology | Series A | $7.8M | $128.3M | 2009 |
| PixelEXX Systems, Inc. | — | Other Technology | Pre-Seed | $625K | $26.5M | 2013 |
Keith Crandell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Keith Crandell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Walt | 3 | 6 |
| David R. Walt | 3 | 5 |
| Paul Meister | 2 | 12 |
| Nelson Chan | 2 | 7 |
| Andrea Jackson | 2 | 6 |
| Robert Carson | 2 | 3 |
| Narbeh Derhacobian | 2 | 2 |
| Kevin Hrusovsky | 2 | 2 |
| John Murphy | 1 | 17 |
| Christopher Brown | 1 | 16 |
| John Connolly | 1 | 14 |
| Mark Levine | 1 | 9 |
| Mark Spoto | 1 | 8 |
| Gregory Johnson | 1 | 8 |
| Josh Wolfe | 1 | 8 |
| Chen Yu | 1 | 7 |
| John Young | 1 | 7 |
| Steven Berger | 1 | 7 |
| John M. Connolly | 1 | 6 |
| T. Peter Thomas | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.